304 related articles for article (PubMed ID: 12100070)
1. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly.
Parkinson C; Renehan AG; Ryder WD; O'Dwyer ST; Shalet SM; Trainer PJ
Clin Endocrinol (Oxf); 2002 Jul; 57(1):59-64. PubMed ID: 12100070
[TBL] [Abstract][Full Text] [Related]
2. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific.
Parkinson C; Ryder WD; Trainer PJ;
J Clin Endocrinol Metab; 2001 Nov; 86(11):5240-4. PubMed ID: 11701684
[TBL] [Abstract][Full Text] [Related]
3. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly.
Dobrashian RD; O'Halloran DJ; Hunt A; Beardwell CG; Shalet SM
Clin Endocrinol (Oxf); 1993 Jun; 38(6):589-93. PubMed ID: 8334745
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults.
Kim HJ; Kwon SH; Kim SW; Park DJ; Shin CS; Park KS; Kim SY; Cho BY; Lee HK
Horm Res; 2001; 56(3-4):117-23. PubMed ID: 11847474
[TBL] [Abstract][Full Text] [Related]
6. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
[TBL] [Abstract][Full Text] [Related]
7. [Lowered ghrelin levels in acromegaly—normalization after treatment].
Kozakowski J; Rabijewski M; Zgliczyński W
Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
[TBL] [Abstract][Full Text] [Related]
8. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy.
Ho KY; Weissberger AJ
Clin Endocrinol (Oxf); 1994 Jul; 41(1):75-83. PubMed ID: 8050134
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
[TBL] [Abstract][Full Text] [Related]
10. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients.
Juul A; Main K; Blum WF; Lindholm J; Ranke MB; Skakkebaek NE
Clin Endocrinol (Oxf); 1994 Jul; 41(1):85-93. PubMed ID: 7519529
[TBL] [Abstract][Full Text] [Related]
11. Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis.
van der Lely AJ; de Herder WW; Janssen JA; Lamberts SW
J Endocrinol; 1997 Oct; 155 Suppl 1():S9-13; discussion S15-6. PubMed ID: 9389990
[TBL] [Abstract][Full Text] [Related]
12. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1.
Parfitt VJ; Flanagan D; Wood P; Leatherdale BA
Clin Endocrinol (Oxf); 1998 Nov; 49(5):647-52. PubMed ID: 10197081
[TBL] [Abstract][Full Text] [Related]
13. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.
Grinspoon S; Clemmons D; Swearingen B; Klibanski A
J Clin Endocrinol Metab; 1995 Mar; 80(3):927-32. PubMed ID: 7533774
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly.
Epaminonda P; Porretti S; Cappiello V; Beck-Peccoz P; Faglia G; Arosio M
Clin Endocrinol (Oxf); 2001 Aug; 55(2):183-9. PubMed ID: 11531924
[TBL] [Abstract][Full Text] [Related]
15. IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly.
de Herder WW; van der Lely AJ; Janssen JA; Uitterlinden P; Hofland LJ; Lamberts SW
Clin Endocrinol (Oxf); 1995 Oct; 43(4):501-5. PubMed ID: 7586626
[TBL] [Abstract][Full Text] [Related]
16. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
Fredstorp L; Kutz K; Werner S
Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
[TBL] [Abstract][Full Text] [Related]
17. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
[TBL] [Abstract][Full Text] [Related]
18. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
[TBL] [Abstract][Full Text] [Related]
19. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
20. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
